AZ and Daiichi Sankyo enter collaboration in novel
This announcement contains inside information The securities proposed to be offered pursuant to the equity placing referred to herein will not be and have not been registered under the US Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. 28 March 2019 23:30 GMT AstraZeneca and Daiichi Sankyo enter collaborationfor novel HER2-targeting antibody-drug conjugate Companies to accelerate and expand development of trastuzumab deruxtecan across breast and other cancers,